Literature DB >> 16575206

Elegance, silence and nonsense in the mutations literature for solid tumors.

Scott E Kern1, Jordan M Winter.   

Abstract

A third of highly cited clinical studies are subsequently contradicted, and there are statistical reasons for why many published research findings may be false. The subjective impression of many experts in cancer genetics is that much of the tumor mutation literature may also be erroneous or deeply flawed. For example, there exist many reports of false somatic mutations attributable entirely to the choice of analytic method. This pattern of mis-reporting may divert the investment of limiting resources for cancer research into fundamentally flawed directions. We provide here a review of the basic theoretic principles and observed patterns within the literature of solid tumors and inherited tumor-susceptibility syndromes. These patterns provide support for a systematic approach to the critical analysis of the somatic mutation literature offered in the accompanying paper.

Entities:  

Mesh:

Year:  2006        PMID: 16575206     DOI: 10.4161/cbt.5.4.2551

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  7 in total

Review 1.  Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy?

Authors:  Tamas A Gonda; Andrea Varro; Timothy C Wang; Benjamin Tycko
Journal:  Semin Cell Dev Biol       Date:  2009-10-17       Impact factor: 7.727

2.  Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors.

Authors:  Karolina Edlund; Ola Larsson; Adam Ameur; Ignas Bunikis; Ulf Gyllensten; Bernard Leroy; Magnus Sundström; Patrick Micke; Johan Botling; Thierry Soussi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-24       Impact factor: 11.205

Review 3.  Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Authors:  Bernard Leroy; Mandy L Ballinger; Fanny Baran-Marszak; Gareth L Bond; Antony Braithwaite; Nicole Concin; Lawrence A Donehower; Wafik S El-Deiry; Pierre Fenaux; Gianluca Gaidano; Anita Langerød; Eva Hellstrom-Lindberg; Richard Iggo; Jacqueline Lehmann-Che; Phuong L Mai; David Malkin; Ute M Moll; Jeffrey N Myers; Kim E Nichols; Sarka Pospisilova; Patricia Ashton-Prolla; Davide Rossi; Sharon A Savage; Louise C Strong; Patricia N Tonin; Robert Zeillinger; Thorsten Zenz; Joseph F Fraumeni; Peter E M Taschner; Pierre Hainaut; Thierry Soussi
Journal:  Cancer Res       Date:  2017-03-15       Impact factor: 12.701

4.  No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas.

Authors:  Wen Qiu; Min Hu; Anita Sridhar; Ken Opeskin; Stephen Fox; Michail Shipitsin; Melanie Trivett; Ella R Thompson; Manasa Ramakrishna; Kylie L Gorringe; Kornelia Polyak; Izhak Haviv; Ian G Campbell
Journal:  Nat Genet       Date:  2008-04-13       Impact factor: 38.330

5.  The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis.

Authors:  Bernard Leroy; Jean Louis Fournier; Chikashi Ishioka; Paola Monti; Alberto Inga; Gilberto Fronza; Thierry Soussi
Journal:  Nucleic Acids Res       Date:  2012-11-17       Impact factor: 16.971

6.  High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays.

Authors:  Roland Houben; Sonja Hesbacher; Corinna P Schmid; Claudia S Kauczok; Ulrike Flohr; Sebastian Haferkamp; Cornelia S L Müller; David Schrama; Jörg Wischhusen; Jürgen C Becker
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

7.  Overexpressed somatic alleles are enriched in functional elements in Breast Cancer.

Authors:  Paula Restrepo; Mercedeh Movassagh; Nawaf Alomran; Christian Miller; Muzi Li; Chris Trenkov; Yulian Manchev; Sonali Bahl; Stephanie Warnken; Liam Spurr; Tatiyana Apanasovich; Keith Crandall; Nathan Edwards; Anelia Horvath
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.